[go: up one dir, main page]

NL301193I2 - tebentafusp - Google Patents

tebentafusp

Info

Publication number
NL301193I2
NL301193I2 NL301193C NL301193C NL301193I2 NL 301193 I2 NL301193 I2 NL 301193I2 NL 301193 C NL301193 C NL 301193C NL 301193 C NL301193 C NL 301193C NL 301193 I2 NL301193 I2 NL 301193I2
Authority
NL
Netherlands
Prior art keywords
tebentafusp
Prior art date
Application number
NL301193C
Other languages
English (en)
Other versions
NL301193I1 (nl
Original Assignee
Immunocore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunocore Ltd filed Critical Immunocore Ltd
Publication of NL301193I1 publication Critical patent/NL301193I1/nl
Publication of NL301193I2 publication Critical patent/NL301193I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NL301193C 2009-07-03 2022-08-15 tebentafusp NL301193I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0911566.8A GB0911566D0 (en) 2009-07-03 2009-07-03 T cell receptors
PCT/GB2010/001277 WO2011001152A1 (en) 2009-07-03 2010-07-01 T cell receptors

Publications (2)

Publication Number Publication Date
NL301193I1 NL301193I1 (nl) 2022-08-17
NL301193I2 true NL301193I2 (nl) 2022-11-24

Family

ID=41008692

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301193C NL301193I2 (nl) 2009-07-03 2022-08-15 tebentafusp

Country Status (19)

Country Link
US (2) US8519100B2 (nl)
EP (1) EP2448963B1 (nl)
JP (2) JP5872464B2 (nl)
CN (3) CN104017067B (nl)
AU (1) AU2010267758C1 (nl)
BR (1) BR112012000107A2 (nl)
CA (1) CA2766505C (nl)
DK (1) DK2448963T3 (nl)
EA (1) EA026918B1 (nl)
ES (1) ES2498190T3 (nl)
FI (1) FIC20220037I1 (nl)
FR (1) FR22C1046I1 (nl)
GB (1) GB0911566D0 (nl)
HK (1) HK1169422A1 (nl)
MX (1) MX2012000155A (nl)
NL (1) NL301193I2 (nl)
PT (1) PT2448963E (nl)
WO (1) WO2011001152A1 (nl)
ZA (1) ZA201109522B (nl)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
EP2760892A1 (en) * 2011-09-29 2014-08-06 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
SG11201404007WA (en) 2012-01-13 2014-08-28 Apo T B V Aberrant cell-restricted immunoglobulins provided with a toxic moiety
CN104395344B (zh) 2012-05-07 2019-08-13 达特茅斯大学理事会 抗b7-h6抗体、融合蛋白及其使用方法
EP2897631A4 (en) 2012-08-31 2016-10-05 Univ Virginia Patent Found TARGET PEPTIDES FOR IMMUNOTHERAPY AND DIAGNOSTICS
EP4088737A3 (en) 2012-09-05 2023-02-08 University Of Virginia Patent Foundation Target peptides for colorectal cancer therapy and diagnostics
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
EP2951202B1 (en) 2013-01-29 2020-04-08 Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; High avidity binding molecules recognizing mage-a1
RU2645256C2 (ru) 2013-06-26 2018-02-19 Гуандун Сянсюэ Лайф Сайенсис, Лтд. Высокостабильный т-клеточный рецептор и способ его получения и применения
EP3071593B1 (en) * 2013-11-22 2019-03-13 The Board of Trustees of the University of Illionis Engineered high-affinity human t cell receptors
DE202014002754U1 (de) 2014-03-31 2015-07-03 Christian Piotrowski Ausgusssystem mit Pullring der mit der Folie verbunden ist.
CA2945816A1 (en) 2014-04-15 2015-10-22 University Of Virginia Patent Foundation Isolated t cell receptors and methods of use therefor
WO2015192757A1 (zh) * 2014-06-18 2015-12-23 广州市香雪制药股份有限公司 高亲和力hcv t细胞受体
US10526391B2 (en) 2014-07-22 2020-01-07 The University Of Notre Dame Du Lac Molecular constructs and uses thereof
CA2956545A1 (en) * 2014-08-04 2016-02-11 Fred Hutchinson Cancer Research Center T cell immunotherapy specific for wt-1
CN119409799A (zh) * 2014-10-02 2025-02-11 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞受体的方法
GB201417803D0 (en) * 2014-10-08 2014-11-19 Adaptimmune Ltd T cell receptors
CN107106670A (zh) * 2014-10-31 2017-08-29 宾夕法尼亚大学董事会 用于修饰的t细胞的方法和组合物
US20190030071A1 (en) 2014-11-03 2019-01-31 IMMURES S.r.I. T cell receptors
GB201506642D0 (en) * 2015-04-20 2015-06-03 Ucl Business Plc T cell receptor
BR112017025332A2 (pt) * 2015-06-01 2018-07-31 Medigene Immunotherapies Gmbh anticorpos específicos de receptor de célula t
JP6568239B2 (ja) * 2015-06-01 2019-08-28 メディジーン イミュノテラピーズ ゲーエムベーハー Ｔ細胞受容体ライブラリ
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201516272D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516277D0 (en) * 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR libraries
CR20220248A (es) 2016-03-16 2022-07-18 Immatics Biotechnologies Gmbh Células t transfectadas y receptores de células t de utilidad en inmunoterapias contra el cáncer
PL3430037T3 (pl) 2016-03-16 2022-12-19 Immatics Biotechnologies Gmbh Transfekowane komórki t oraz receptory komórek t do stosowania w immunoterapii przeciwnowotworowej
GB201604953D0 (en) 2016-03-23 2016-05-04 Immunocore Ltd T cell receptors
JP6908621B2 (ja) 2016-03-28 2021-07-28 ダウ グローバル テクノロジーズ エルエルシー ２成分無溶剤接着剤組成物及びその作製方法
PT3464380T (pt) 2016-06-02 2025-02-06 Immunocore Ltd Regime de dosagem para proteína de fusão de tcr específico de gp100 - scfv anti-cd3
MD3500593T2 (ro) 2016-08-17 2021-12-31 Immatics Biotechnologies Gmbh Receptori de celule T și imunoterapie cu utilizarea acestora
DE102016115246C5 (de) 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
JP2020501508A (ja) * 2016-09-15 2020-01-23 クアドルセプト バイオ リミテッド 多量体、四量体および八量体
GB201617714D0 (en) 2016-10-19 2016-11-30 Ucl Business Plc T Cell receptor
SG11201908527SA (en) 2017-03-15 2019-10-30 Hutchinson Fred Cancer Res High affinity mage-a1-specific tcrs and uses thereof
DE102017106305A1 (de) 2017-03-23 2018-09-27 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
GB201709866D0 (en) 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors
EA202090812A1 (ru) 2017-09-22 2020-08-07 Уси Байолоджикс Аэлэнд Лимитед Новые биспецифические полипептидные комплексы
MX2020003144A (es) 2017-09-22 2020-07-28 Wuxi Biologics Ireland Ltd Nuevos complejos de polipeptidos biespecificos cd3/cd19.
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS
CN109776671B (zh) * 2017-11-14 2022-05-27 杭州康万达医药科技有限公司 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用
WO2020028595A2 (en) * 2018-07-31 2020-02-06 Janux Therapeutics, Inc. Inhibitory t cell receptor peptides and discovery methods
JP7558151B2 (ja) 2018-09-05 2024-09-30 アダプティミューン・リミテッド Ｔ細胞改変
US20220080030A1 (en) 2019-01-17 2022-03-17 Immunocore Limited Formulations
GB201901306D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
GB201902277D0 (en) 2019-02-19 2019-04-03 King S College London Therapeutic agents
JP2022535924A (ja) * 2019-06-06 2022-08-10 ジャナックス セラピューティクス，インク． 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法
US20220281949A1 (en) * 2019-07-30 2022-09-08 University Health Network Mhc class ii molecules and methods of use thereof
CN111234004B (zh) * 2020-02-28 2023-03-28 陕西九州新药评价研究有限公司(西安新药评价研究中心) 识别wt1抗原短肽的t细胞受体及其应用
GB202006629D0 (en) * 2020-05-05 2020-06-17 Immunocore Ltd Specific binding molecules
AU2021276264A1 (en) * 2020-05-18 2022-12-22 Board Of Regents, The University Of Texas System Engineered T cell receptors and methods of use
CN112239495B (zh) * 2020-10-29 2022-04-12 上海药明生物技术有限公司 稳定的tcr结构及应用
CN114853879A (zh) * 2021-02-03 2022-08-05 香雪生命科学技术（广东）有限公司 一种识别hpv的t细胞受体
WO2022258606A1 (en) 2021-06-07 2022-12-15 Gadeta B.V. Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
US12103971B2 (en) 2022-02-20 2024-10-01 Immunocore Limited HIV specific binding molecules
WO2023227594A1 (en) 2022-05-24 2023-11-30 Gadeta Bv Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof
WO2023237541A1 (en) 2022-06-07 2023-12-14 Gadeta B.V. Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
WO2023246911A1 (zh) * 2022-06-24 2023-12-28 北京可瑞生物科技有限公司 基于t细胞受体的双特异性多肽分子及其用途
WO2024013402A1 (en) 2022-07-15 2024-01-18 Gadeta B.V. Novel soluble gamma t-cell (or soluble delta t-cell) receptor chains (or soluble gammadelta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
AR130245A1 (es) 2022-08-18 2024-11-20 Immunocore Ltd Moléculas de unión multidominio
WO2024038183A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
AU2023326814A1 (en) 2022-08-18 2025-03-06 Immunocore Limited Multi-domain binding molecules
WO2024067821A1 (zh) * 2022-09-30 2024-04-04 瑅安生物医药（杭州）有限公司 一种修饰细胞及其用途
WO2024130179A1 (en) 2022-12-16 2024-06-20 Repertoire Immune Medicines, Inc. T cell receptors binding hpv-16 epitopes
WO2024260454A1 (zh) * 2023-06-21 2024-12-26 北京可瑞生物科技有限公司 经修饰的tcr恒定区及其在tcr融合蛋白中的用途
CN118108833A (zh) * 2024-03-12 2024-05-31 缇纱(合肥)生物技术有限公司 引入外源二硫键的tcr恒定区及其产品和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688747A (en) 1994-08-22 1997-11-18 Becton Dickinson And Company Water based lubricant solution
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
AU746164B2 (en) * 1998-05-19 2002-04-18 Avidex Limited Soluble T cell receptor
PL208712B1 (pl) * 2001-08-31 2011-05-31 Avidex Ltd Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd
JP4975324B2 (ja) 2002-11-09 2012-07-11 イムノコア リミテッド Ｔ細胞レセプターディスプレイ
GB0227351D0 (en) * 2002-11-22 2002-12-31 Isis Innovation Soluble T-cell receptors
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
CN101035561A (zh) * 2004-03-24 2007-09-12 特罗斯药品公司 作为改善对疫苗的免疫反应的佐剂的组合物和使用方法
ATE408684T1 (de) 2004-05-19 2008-10-15 Medigene Ltd Verfahren zur verbesserung von t-zellrezeptoren
GB0411125D0 (en) * 2004-05-19 2004-06-23 Avidex Ltd Method of improving T-cell receptors
EP1791865B1 (en) 2004-06-29 2010-07-28 Immunocore Ltd. Cells expressing a modified t cell receptor
US20060045884A1 (en) * 2004-08-26 2006-03-02 Board Of Regents Vaccines for autoimmune and infectious disease
WO2006031221A1 (en) * 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
WO2006054096A2 (en) * 2004-11-18 2006-05-26 Avidex Ltd Soluble bifunctional proteins
JP5214252B2 (ja) * 2005-03-03 2013-06-19 イミューノメディクス、インコーポレイテッド ヒト化ｌ２４３抗体
GB0511124D0 (en) 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
EP1795599A1 (en) * 2005-12-09 2007-06-13 Schuler, Gerold, Prof. Dr. Methods for generating antigen-specific effector T cells
CA2651174A1 (en) 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
EP2087000A2 (en) 2006-09-29 2009-08-12 Immunocore Ltd. T cell therapies
CA2674445C (en) 2007-01-12 2016-06-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Gp100-specific t cell receptors and related materials and methods of use
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors

Also Published As

Publication number Publication date
EP2448963B1 (en) 2014-06-04
EP2448963A1 (en) 2012-05-09
PT2448963E (pt) 2014-09-01
JP5872464B2 (ja) 2016-03-01
BR112012000107A2 (pt) 2016-11-01
US9068178B2 (en) 2015-06-30
CN104017067B (zh) 2017-11-03
AU2010267758B2 (en) 2014-09-04
CN102574906A (zh) 2012-07-11
AU2010267758C1 (en) 2015-01-22
EA026918B1 (ru) 2017-05-31
ZA201109522B (en) 2013-05-29
US20120225481A1 (en) 2012-09-06
US20140099699A1 (en) 2014-04-10
JP2012531904A (ja) 2012-12-13
DK2448963T3 (da) 2014-08-25
JP6186412B2 (ja) 2017-08-23
NL301193I1 (nl) 2022-08-17
CA2766505A1 (en) 2011-01-06
US8519100B2 (en) 2013-08-27
WO2011001152A1 (en) 2011-01-06
GB0911566D0 (en) 2009-08-12
EA201270135A1 (ru) 2012-09-28
CA2766505C (en) 2019-01-22
FR22C1046I1 (fr) 2022-10-14
FIC20220037I1 (fi) 2022-08-31
JP2016039812A (ja) 2016-03-24
AU2010267758A1 (en) 2012-02-09
CN107266560A (zh) 2017-10-20
MX2012000155A (es) 2012-06-28
ES2498190T3 (es) 2014-09-24
HK1169422A1 (en) 2013-01-25
CN104017067A (zh) 2014-09-03

Similar Documents

Publication Publication Date Title
FIC20220037I1 (fi) Tebentafuspi
DK2414015T3 (da) Laryngoskopsystem
DK2411442T4 (da) Umættet polyesterresin
DE112010004215A5 (de) Hydrostataktor
DE112010002949A5 (de) Kupplungstastpunkte
EP2445547A4 (en) CATHETERISM SYSTEM
EP2397521A4 (en) BENZOXAZINE RESIN COMPOSITION
EP2407456A4 (en) CARBAZOLE ESTER-OXIME PHOTOINITIATOR
EP2401340A4 (en) POLYMER MODIFIER AGENTS
DK2430035T3 (da) Uracylspipooxetannukleosider
BRPI1008827A2 (pt) deisobutenizador
EP2509489A4 (en) SPRINKLER FOR EARLY HEEL REMOVAL
BRPI1014968A2 (pt) subalargador
DE112010002728A5 (de) Turboinhalator
DE112009005323A5 (de) Hebelarmprüfmaschine
DE112010004249A5 (de) Spindelaktor
DE112009005462T8 (de) Lenkungsssteuervorrichtung
BR112012004964A2 (pt) girocóptero
BRPI1008070A2 (pt) tricianoboratos
DK2483126T3 (da) Skinnekøretøj
EP2402744A4 (en) CARBURATION DETECTION METHOD
EP2409976A4 (en) GLYCINE TRANSPORTER INHIBITOR
EP2401281A4 (en) PYRIMIDO-PYRIMIDO-INDAZOLE DERIVATIVE
DE112010004865T8 (de) Lamellennassreibkupplung
DK2506968T3 (da) Faujasit-zeolit